Research programme: antisense drug therapies - Amgen/Isis
Alternative Names: Antisense drug therapies research programme - Amgen/Isis; Antisense oligonucleotides research programme - Amgen/Isis; Research programme: antisense oligonucleotides - Amgen/IsisLatest Information Update: 27 Jul 2005
At a glance
- Originator Amgen; Isis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Dec 2004 Discontinued - Preclinical for Undefined in USA (unspecified route)
- 17 Dec 2001 New profile
- 17 Dec 2001 Preclinical development for Undefined in USA (Unknown route)